Research programme: anticancer therapeutics - GVK Biosciences/Onconova Therapeutics

Drug Profile

Research programme: anticancer therapeutics - GVK Biosciences/Onconova Therapeutics

Alternative Names: GBO-006; ON 1231320

Latest Information Update: 26 May 2015

Price : $50

At a glance

  • Originator GVK BIO; Onconova Therapeutics
  • Class Small molecules
  • Mechanism of Action Polo-like kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer

Most Recent Events

  • 21 Apr 2015 Preclinical trials in Breast cancer in USA (unspecified route)
  • 21 Apr 2015 Preclinical trials in Cancer in USA (unspecified route)
  • 09 Jan 2013 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top